The researchers tested their hypothesis that a decrease in respiratory virus incidence would be associated with a reduction in inappropriate ambulatory antibiotic orders.
An emerging body of research highlights plant-based vaccine manufacturing as a potential solution to risks posed by traditional egg-based manufacturing.
Study authors evaluated influenza-vaccinated patients hospitalized with an influenza-like illness to identify characteristics associated with being at increased risk for hospitalization with influenza.
There may be increased hospitalization risk from influenza infection in patients with obstructive sleep apnea who do not use continuous positive airway pressure.
Investigators used precision surveillance by combining genomic sequencing and conventional surveillance to delineate a nosocomial viral outbreak; they believe the findings of their study are applicable to a range of respiratory pathogens, including SARS-CoV-2.
Either the trivalent adjuvanted inactivated influenza vaccine (aIIV3) or the trivalent high-dose inactivated influenza vaccine (HD-IIV3) is safe to use in older adults.
For patients with high-risk CVD, high-dose trivalent inactivated influenza vaccination does not reduce cardiopulmonary hospitalization or all-cause mortality.
Study authors identified and evaluated a statistical signal for an increased risk of Guillain-Barré Syndrome in days 1-42 after 2018-2019 high-dose influenza vaccine administration.
Researchers conducted a retrospective cohort study to compare characteristics of children with a confirmed diagnosis of COVID-19, seasonal influenza A, and influenza B.
